Echo Therapeutics, Inc. (Echo) is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market and the diabetes outpatient market. The Company offers continuous glucose monitoring, drug delivery and specialty pharmaceutical products. The Company's lead product is a non-invasive (needle-free), wireless, continuous glucose monitoring system designed to provide real-time glucose data. The Company's skin preparation device also has application in the transdermal drug delivery market. The Company's transdermal drug reformulation platform, AzoneTS, is a penetration enhancer at low concentration levels. The Company's drug candidate, Durhalieve is an AzoneTS formulation of triamcinolone acetonide, a medium potency corticosteroid for treatment of corticosteroid-responsive dermatoses.